*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Abstract: Antibody production is an important component of the mechanism of action of anti-coronavirus vaccines, and high-affinity antibodies are also useful reagents in diagnostics and potential therapeutic applications. This presentation will update last year’s talk on our development of monoclonal antibodies and the characterization of their different functional properties with respect to coronavirus binding and neutralization.
Bio: M.G. Finn received his Ph.D. degree in 1986 from the Massachusetts Institute of Technology working with Prof. K.B. Sharpless, followed by an NIH postdoctoral fellowship at Stanford University. He joined the faculty of the University of Virginia in 1988, where his group studied and developed a variety of transition metal-mediated reactions for use in synthetic chemistry. Prof. Finn moved to the Department of Chemistry and The Skaggs Institute for Chemical Biology at The Scripps Research Institute in 1998, and then to Georgia Tech in 2013. His current interests include the use of virus particles as molecular and catalytic building blocks for vaccine and functional materials development, the discovery of click reactions for organic and materials synthesis, polyvalent interactions in drug targeting, and the use of evolution for the discovery of chemical function. He was the first recipient of the annual Scripps Outstanding Mentor Award, and is Chief Scientific Officer of the Children’s Healthcare of Atlanta Pediatric Technology Center at Georgia Tech.
